Launch of Wegovy pill is core to Novo Nordisk's growth, says Guggenheim's Seamus Fernandez

for more in its first ever GLP1 pill. Guggenheim partner Sheamus Fernandez joins us now. He is the firm's managing director and pharma analyst.Sheamus, great to have you with us. >> Nice to see you. >> Does this change the competitive landscape at all with Eli Liy's or four coming on um and and some other competitors coming, you know, down the pike.>> It's a great question. I mean, I think it doesn't necessarily change the competitive landscape that dramatically. Um but it does give Novo an opportunity to g ...